Can HPC help cure Pharma R&D?

Philippe GUILLET
Chief Geriatrician, SANOFI

Cliquez ICI pour télécharger la présentation

Abstract : The past few decades have seen a decrease in Pharma R&D productivity, and the former approach of seeking for the “one size fits all” blockbuster seems to be on the way to soon be replaced by the “Individualized Medicine” paradigm, where drug treatments will be customized, based on the integration of various “-omics” data collected from the patients. Translational and system’s medicine promise to help realize this transformation. Integration of basic research and clinical practice, and interpretation of clinical and nonclinical data for diagnosis, prognosis, and therapy will require advanced computational, simulation and mathematical tools.

Biographie : Philippe GUILLET, M.D. after completing his medical studies at the Pitié-Salpétrière Hospital, specialized in Geriatrics and Gerontology, and practiced for about 10 years at the Charles-Foix Hospital, the largest Geriatric Hospital in France. He then joined the Pharmaceutical Industry and spent his carrier in the Clinical Development field, leading (among others) the Clinical Development of Rilutek (riluzole in Amyotrophic Lateral Sclerosis - Lou Gehrig’s disease). He currently works in the Therapeutic Strategic Unit Aging, at Sanofi R&D.